The FDA granted galinpepimut-S a rare pediatric disease designation for the treatment of pediatric patients with acute ...

The FDA grants rare pediatric disease designation for serious or life-threatening diseases that affect fewer than 200,000 people in the United States when those people are primarily younger than 18 ...

SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company, Tuesday announced that the U.S. Food and ...

GPS Currently Investigated in Phase 3 REGAL Trial in Adult AML Patients – Interim Analysis Anticipated in Q4 2024 - ...

The agent is currently being evaluated in a phase 1a study, and a phase 1b/2a study will continue to assess LP-184’s safety ...

10月18日，北极光投资企业 血霁生物 宣布自主研发的“全球新” Fisrt-in-Class细胞治疗产品XJ-MK-002 治疗先天性无巨核细胞性血小板减少症获得美国食品药品监督管理局（FDA）认证授予儿科罕见病资格认定（Rare ...

Theriva Biologics (NYSE American: TOVX), ("Theriva” or the "Company”), a clinical-stage company developing therapeutics ...

Options Medical Weight Loss, the nation's premier medical weight loss clinic, is eager to announce the re-opening of its state-of-the-art clinic in Cary, North Carolina! Options plans to host a ...

HemoSonics, LLC, a medical device company focused on acute bleeding management, today announced it has been awarded one of ...

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and ...

The FDA has granted Atsena an Orphan Drug Designation for ATSN-201, the company’s product candidate targeting X-linked retinoschisis (XLRS), a rare genetic disease that causes blindness, mostly among ...

The FDA grants rare pediatric disease designation for serious or life-threatening diseases that affect fewer than 200,000 people in the United States when those people are primarily younger than ...